Primidone
Primidone
Generic Name
Primidone
Mechanism
Primidone exerts its therapeutic effect primarily by modulating GABAergic neurotransmission through several overlapping mechanisms:
• Prodrug conversion – hepatic CYP-mediated hydrolysis to phenobarbital and EPM.
• Potentiation of GABAA receptors – increased chloride ion influx into neurons, hyperpolarizing the membrane.
• Sodium‑channel blockade – stabilizes the inactive state of voltage‑gated Na⁺ channels, reducing high‑frequency firing.
• Calcium‑channel inhibition – decreases presynaptic Ca²⁺ influx, lowering excitatory neurotransmitter release.
• Modulation of potassium channels – enhances K⁺ conductance, contributing to neuronal membrane stabilization.
Pharmacokinetics
| Parameter | Details |
| Absorption | Rapid oral absorption; peak plasma levels reach 60–90 min post‑dose. |
| Bioavailability | 70–80 % (first‑pass metabolism). |
| Distribution | Widely distributed; high plasma protein binding (~92 %). |
| Half‑life | ~20–30 h for primidone; ~18–25 h for phenobarbital; ~20 h for EPM. |
| Metabolism | Hepatic CYP2C19, CYP2C9, CYP2B6 convert primidone → phenobarbital/EPM; autoinduction of CYP1A2/3A4 occurs with prolonged therapy. |
| Excretion | Renally (≈50 % unchanged); biliary excretion also significant. |
Indications
- Partial‑onset seizures (excluding myoclonic/familial form).
- Generalized tonic‑clonic seizures.
- Status epilepticus (adjuvant).
- Essential tremor (when first‑line agents are contraindicated or ineffective).
- Racine‑type seizure disorders in resource‑limited settings.
Contraindications
Contraindications
• Known hypersensitivity to primidone, phenobarbital, or barbiturates.
• Severe hepatic or renal impairment.
• Current treatment with potent CYP1A4 inhibitors (e.g., cimetidine).
• Severe sinus bradycardia or sick sinus syndrome.
Warnings
• Sedation & respiratory depression—caution in combinations with CNS depressants.
• Photo‑sensitivity—sun exposure increases rash risk.
• Drug interactions – induces CYP enzymes; may reduce efficacy of oral contraceptives, warfarin, and other AEDs.
• Pregnancy – category C; should be used only if benefits outweigh risks.
• Lactation – contraindicated; drug is excreted in breast milk.
Dosing
| Indication | Starting Dose | Titration | Maintenance Dose | Notes |
| Partial seizures | 250 mg/day | +250 mg every 1–2 weeks | 2000–3500 mg/day (divide ×3) | Target plasma phenobarbital ~120–250 μg/mL. |
| Generalized tonic‑clonic | 250 mg/day | +250 mg at 1 week intervals | ≤3000 mg/day | Avoid exceeding 3000 mg/day due to toxicity. |
| Status epilepticus | 100 mg/kg IV over 30 min | None (mal short‑term) | – | Use only after benzodiazepine failure. |
| Essential tremor | 250 mg/day | +250 mg every 2 weeks | 1000–2000 mg/day | Monitor for tremor worsening and cognitive side‑effects. |
• Administration: orally with a full glass of water.
• Meal effect: food delays absorption; recommend dosing on an empty stomach for faster onset.
Adverse Effects
Common (≥10 %)
• Sedation, drowsiness, ataxia
• Nausea, vomiting, dyspepsia
• Dizziness, orthostatic hypotension
• Headache, tremor, rash (often contact dermatitis)
Serious (≤1 %)
• Hepatotoxicity (↑AST/ALT, jaundice) – rare but life‑threatening.
• Severe allergic reactions (anaphylaxis, Stevens–Johnson syndrome).
• Severe CNS depression leading to respiratory arrest (especially when combined with opioids or benzodiazepines).
• Metabolic alkalosis (rare).
Monitoring
- Baseline: CBC, LFTs, electrolytes, renal panel, pregnancy test (if applicable).
- Therapeutic drug monitoring: phenobarbital levels 2–4 weeks after achieving a steady state, repeat every 3–6 months thereafter.
- Liver function: every 3–6 months, more frequently if LFTs rise >2× ULN.
- Serum electrolytes: check if significant diuresis or vomiting.
- Clinical assessment: seizure frequency, tremor activity, sedation scores.
- Drug‑interaction checks: review concomitant meds at each clinic visit.
Clinical Pearls
- Prodrug advantage: Primidone’s active metabolites (phenobarbital/EPM) provide dual seizure‑control mechanisms, but also carry the risk of barbiturate‑like sedation.
- Autoinduction: The drug induces its own metabolism, necessitating dose escalations over time to maintain plasma levels.
- Titration strategy: Slow, incremental increases (≤250 mg every 1–2 weeks) help prevent adverse effects; stability achieved after 8–10 weeks.
- Barbiturate sandwich: In status epilepticus, primidone can act as a “barbiturate sandwich” (benzodiazepine → primidone) to suppress refractory seizures, but carry heightened overdose risk.
- EPM monitoring: When available, EPM levels may better correlate with efficacy in focal seizures compared to phenobarbital alone.
- Tremor nuances: Phenobarbital’s GABA‑enhancing effect can paradoxically lower or worsen tremor; individualized dosing is essential.
- Withdrawal caution: Sudden discontinuation can precipitate seizure or withdrawal hyperexcitability; taper over at least 4 weeks.
- Drug‑drug interaction catch‑all: Be vigilant for interactions with valproic acid (increased liver toxicity) and clonazepam (additive sedation).
--
• Primidone remains a valuable, cost‑effective anti‑epileptic, particularly in settings where newer agents are unavailable or unaffordable. Mastery of its pharmacodynamics, careful titration, and vigilant monitoring will maximize benefit and minimize risk for patients.